Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 567-576

  Presland, Jeremy ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allosteric; G protein coupled receptor; Modulator; Orthosteric

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3,3' DICHLOROBENZALDAZINE; 3,3' DIFLUOROBENZALDAZINE; 3,3' DIMETHOXYBENZALDAZINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; CGP 7930; CINACALCET; EGLUMETAD; G PROTEIN COUPLED RECEPTOR; METABOTROPIC RECEPTOR AGONIST; T 62; UNCLASSIFIED DRUG;

ALLOSTERISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; REVIEW; SECOND MESSENGER; THIOCHROME;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 24044493211     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov (2002) 1(9):727-730.
2. Tsai BS, Lefkowitz RJ: Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled α adrenergic receptors in rabbit platelets. Mol Pharmacol (1978) 14(4):540-548.
3. + and GTP. Proc Natl Acad Sci USA (1979) 76(11):5626-5630.
4. Kenakin T: Allosteric modulators: The new generation of allosteric antagonist. Mol Interventions (2004) 4(4):222-229.
5. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin JP, Cambria A et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[6] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem (2000) 275(43):33750-33758.
6. B receptor.
7. Johnston PA, Johnston PA: Cellular platforms for HTS: Three case studies. Drug Disc Today (2003) 7(6):353-363.
8. GPCR assay trends 2004 market report: HTStec Ltd, Cambridge, UK http://www.htstec.com/consultancyitem.aspx?Item=127
9. Henry B: GPCR allosterism and accessory proteins: New insights into drug discovery. IDrugs (2004) 7(9):819-821.
10. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol (1998) 53(6):1083-1088.
11. aq/15 stimulate intracellular calcium mobilisation in transfected HEK 293 cells. Third Annual European Conference on GPCRs in Drug Discovery, Amsterdam, the Netherlands (2005).
12. 4 receptors: Receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol (2004) 65(1):257-266. Defines the concept of absolute subtype selectivity through co-operativity rather than affinity.
13. Hall DA: Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol Pharmacol (2000) 58(6):1412-1423.
14. Kenakin T: Principles: Receptor theory in pharmacology. Trends Pharmacol Sci (2000) 25(4):186-192.
15. Christopoulos A, Kenakin T: G protein-coupled receptor allosterism and complexing. Pharmacol Rev (2002) 54(2):323-374. Recommended reading for gaining an insight into the theoretical and practical complexities of allosteric interactions.
16. Zahn K, Eckstein N, Trankle C, Sadee W, Mohr K: Allosteric modulation of muscarinic receptor signaling: Alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther (2002) 301(2):720-728.
17. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santon EM, Flor PJ, Allgeier H, Gasparini F et al: SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther (1999) 290(1):170-181.
18. Kew JN: Positive and negative allosteric modulation of metabotropic glutamate receptors: Emerging therapeutic potential. Pharmacol Ther (2004) 104(3):233-244.
19. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, Duggan ME et al: A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther (2004) 309(2):568-577.
20. O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ et al: A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol (2003) 64(3):731-740. Seminal paper demonstrating that extremely small changes in chemical structure can result in dramatic functional consequences.
21. 1 cannabinoid receptor. BioScience 2004 Satellite Meeting - GPCR Allosterism and Accessory Proteins: Insights into Drug Discovery, Newhouse, Glasgow, UK (2004).
22. 1 receptor. Mol Pharmacol (2005): manuscript submitted.
23. Conigrave AD, Franks AH: Allosteric activation of plasma membrane receptors - physiological implications and structural origins. Prog Biophys Mol Biol (2003) 81(3):219-240.
24. Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG: Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA (1997) 94(25):14115-14119.
25. 7A receptor by lipidic amphipathic compounds. Mol Pharmacol (2001) 60(6):1349-1355.
26. 2+-sensing receptor. Proc Natl Acad Sci USA (2000) 97(9):4814-4819.
27. 1D receptors expressed in transfected cultured cells. Naunyn Schmiedebergs Arch Pharmacol (1998) 358(3):279-286.
28. 1B/1D receptors. Mol Pharmacol (1996) 50(4):752-762.
29. Moret C, Grimaldi B, Massot O, Fillion G: The role and therapeutic potential of 5-HT-moduline in psychiatry. Semin Clin Neuropsychiatry (2003) 8(2):137-146.
30. Clenet F, Hascoet M, Fillion G, Galons H and Bourin M: Anxiolytic profile of HG1, a 5-HT-moduline antagonist, in three mouse models of anxiety. Eur Neuropsychopharmacol (2004) 14(6):449-456. Introduces the first compound designed to competitively inhibit an endogenous modulator.
31. Clenet F, Hascoet M, Fillion G, Galons H, Bourin M: Role of GABAergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res (2005) 158(2):339-348.
32. Grillon C, Cordova J, Levine LR, Morgan CA 3rd: Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm In humans. Psychopharmacology (Berl) (2003) 168(4):446-454.
33. 2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: Preliminary results. Psychopharmacology (Berl) (2005) 179(1):310-315.
34. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE: Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol (2003) 63(3):751-765.
35. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res (2000) 34(3):171-181.
36. Holsboer F: Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs (2003) 4(1):46-50.
37. King Pharmaceutical Inc: King Pharmaceuticals commences phase I clinical trial for neuropathic pain drug. Press Release (2003) November 12. http://www.kingpharm.corn/news_details.asp?id_news=258
38. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G: Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol (2004) 491(2-3):137-148.
39. 1 receptor produces tolerance in rats with neuropathic pain. Anesthesiology (2004) 100(4):956-961.
40. Obata H, Li X, Eisenach JC: Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury. Anesthesiology (2004) 100(5):1258-1262.
41. 1 receptor coupling to G proteins in brain. J Neurochem (2005) 93(3):715-723.
42. 2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol (1991) 39(6):733-739.
43. 2-like dopamine receptors through distinct molecular mechanisms. J Pharmacol Exp Ther (1999) 289(2):956-964.
44. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol (1990) 38(6):939-949.
45. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol (2001) 60(5):1057-1063.
46. 4 dopamine receptors by amiloride and amilorlde analogues. Br J Pharmacol (2000) 130(5):1045-1059.
47. Watson C, Jenkinson S, Kazmierski W, Kenakin T: The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol (2005) 67(4):1268-1282.
48. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, Hacker C, Hagmann WK, MacCoss M, Chicchi GG, Vicario PP: Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem (1999) 274(13):8694-8697.
49. 3H]R214127: A novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol (2003) 63(5):1082-1093.
50. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA: Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action and binding site. Proc Natl Acad Sci USA (2001) 98(23):13402-13407.
51. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD: Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)-phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem (2003) 46(15):3189-3192.
52. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT: Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol (2003) 138(6):1026-1030.
53. B receptors by 2,6-di-tert-butyl-4-(3- hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol (2001) 60(5):963-971.